In conclusion, since it has been shown that CK2 gene amplification is a marker of poor prognosis in NSCLC (O-charoenrat et al., 2004), a therapy that specifically inhibits CK2 may be particularly effective by inducing restoration of PML and its tumor suppressive functions. This evidence concerns the gene PML and non-small cell lung carcinoma.